Inventor · disambiguated record
Aris Baras
Also filed as: BARAS ARIS · BARAS ARIS I
39 granted patents·54 pending applications·48 citations·filing 2014–2025
96Inventor score
Top patents by PatentIndex Score
93 records- 0195US11180757B117β-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2021·Granted Nov 23, 2021·3 cites·30 claims
- 0294US11702700B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2021·Granted Jul 18, 2023·4 cites·27 claims
- 0394US10787647B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2018·Granted Sep 29, 2020·10 cites·52 claims
- 0492US11957704B2Methods of treating metabolic disorders and cardiovascular disease with inhibin subunit beta E (INHBE) inhibitorsREGENERON PHARMA·Filed 2022·Granted Apr 16, 2024·2 cites·11 claims
- 0592US11939635B2Treatment of obesity in subjects having variant nucleic acid molecules encoding Calcitonin Receptor (CALCR)REGENERON PHARMA·Filed 2021·Granted Mar 26, 2024·2 cites·20 claims
- 0692US11753628B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2022·Granted Sep 12, 2023·1 cites·26 claims
- 0792US10961583B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2018·Granted Mar 30, 2021·9 cites·29 claims
- 0891US11759476B2Methods of treating metabolic disorders and cardiovascular disease with Inhibin Subunit Beta E (INHBE) inhibitorsREGENERON PHARMA·Filed 2022·Granted Sep 19, 2023·2 cites·16 claims
- 0988US9963501B2B cell lineage based immunogen design with humanized animalsREGENERON PHARMA·Filed 2014·Granted May 8, 2018·6 cites·14 claims
- 1087US11584966B2Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereofREGENERON PHARMA·Filed 2020·Granted Feb 21, 2023·2 cites·8 claims
- 1186US2024141305A1Hsd17b13 variants and uses thereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 1285US11359246B2Treatment of obesity with G-protein coupled receptor 75 (GPR75) inhibitorsREGENERAN PHARMACEUTICALS INC·Filed 2021·Granted Jun 14, 2022·1 cites·29 claims
- 1384US12286677B2Inhibition of HSD17B13 in the treatment of liver disease in patients expressing the PNPLA3 I148M variationREGENERON PHARMA·Filed 2023·Granted Apr 29, 2025·0 cites·14 claims
- 1484US11845963B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2018·Granted Dec 19, 2023·1 cites·12 claims
- 1584US11820982B2Treatment of ophthalmic conditions with son of Sevenless 2 (SOS2) inhibitorsREGENERON PHARMA·Filed 2021·Granted Nov 21, 2023·1 cites·7 claims
- 1684US11674177B2Kelch domain containing 7B (KLHDC7B) variants and uses thereofREGENERON PHARMA·Filed 2021·Granted Jun 13, 2023·1 cites·10 claims
- 1784US11485958B2HSD17B13 variants and uses thereofREGENERON PHARMA·Filed 2020·Granted Nov 1, 2022·1 cites·40 claims
- 1881US12258627B2Kelch domain containing 7B (KLHDC7B) variants and uses thereofREGENERON PHARMA·Filed 2023·Granted Mar 25, 2025·0 cites·19 claims
- 1981US2024252528A1Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2080US2023031669A1Hsd17b13 variants and uses thereofREGENERON PHARMA·Filed 2022·Application pending·0 cites
- 2178US11708415B2Treatment and inhibition of inflammatory lung diseases in patients having risk alleles in the genes encoding IL33 and IL1RL1REGENERON PHARMA·Filed 2019·Granted Jul 25, 2023·1 cites·18 claims
- 2278US2025122574A1Piezo Type Mechanosensitive Ion Channel Component 1 (PIEZO1) Variants And Uses ThereofREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2377US12234460B2Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitorsREGENERON PHARMA·Filed 2023·Granted Feb 25, 2025·0 cites·25 claims
- 2477US10626168B2B cell lineage based immunogen design with humanized animalsREGENERON PHARMA·Filed 2018·Granted Apr 21, 2020·1 cites·18 claims
- 2576US2025333737A117ß-HYDROXYSTEROID DEHYDROGENASE TYPE 13 (HSD17B13) iRNA COMPOSITIONS AND METHODS OF USE THEREOFREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 2675US12163192B2Piezo type mechanosensitive ion channel component 1 (PIEZO1) variants and uses thereofREGENERON PHARMA·Filed 2023·Granted Dec 10, 2024·0 cites·9 claims
- 2775US2024376471A1Treatment of Liver Diseases With Cell Death Inducing DFFA Like Effector B (CIDEB) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2874US2024182973A1Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR)REGENERON PHARMA·Filed 2024·Application pending·0 cites
- 2974US2024148774A1Treatment Of Inflammation With Glucocorticoids And Angiopoietin-Like 7 (ANGPTL7) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3074US2025305050A1Inhibition Of HSD17B13 In The Treatment Of Liver Disease In Patients Expressing The PNPLA3 I148M VariationREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3174US2025170226A1Methods Of Treating Skin Cancer With Histidine Ammonia-Lyase (HAL) AgonistsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3273US2025188473A1Methods Of Treating Liver Diseases With Phosphodiesterase 3B (PDE3B) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 3373US2024102013A1Treatment Of Ophthalmic Conditions With Son of Sevenless 2 (SOS2) InhibitorsREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3472US11891607B2Methods of treating decreased bone mineral density with cluster of differentiation 109 (CD109) inhibitorsREGENERON PHARMA·Filed 2022·Granted Feb 6, 2024·0 cites·18 claims
- 3572US2022184114A1Methods Of Treating Metabolic Disorders And Cardiovascular Disease With Inhibin Subunit Beta E (INHBE) InhibitorsREGENERON PHARMA·Filed 2021·Application pending·0 cites
- 3672US2025250631A1Kelch Domain Containing 7B (KLHDC7B) Variants And Uses ThereofREGENERON PHARMA·Filed 2025·Application pending·0 cites
- 3771US12018259B2Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitorsREGENERON PHARMA·Filed 2021·Granted Jun 25, 2024·0 cites·22 claims
- 3871US2024075102A1Macrophage Stimulating 1 Receptor (MST1R) Variants And Uses ThereofREGENERON PHARMA·Filed 2023·Application pending·0 cites
- 3970US12359201B217ß-hydroxysteroid dehydrogenase type 13 (HSD17B13) iRNA compositions and methods of use thereofREGENERON PHARMA·Filed 2019·Granted Jul 15, 2025·0 cites·39 claims
- 4070US12123001B2Methods of treating liver diseases with phosphodiesterase 3B (PDE3B) inhibitorsREGENERON PHARMA·Filed 2022·Granted Oct 22, 2024·0 cites·14 claims
- 4170US11865134B2Treatment of inflammation with glucocorticoids and angiopoietin-like 7 (ANGPTL7) inhibitorsREGENERON PHARMA·Filed 2022·Granted Jan 9, 2024·0 cites·3 claims
- 4270US11773393B2Treatment of liver diseases with cell death inducing DFFA like effector B (CIDEB) inhibitorsREGENERON PHARMA·Filed 2022·Granted Oct 3, 2023·0 cites·27 claims
- 4370US2023374145A1Treatment And Inhibition Of Inflammatory Lung Diseases In Patients Having Risk Alleles In The Genes Encoding IL33 And IL1RL1REGENERON PHARMA·Filed 2023·Application pending·0 cites
- 4470US2025197866A1Treatment Of Liver Disease With Mitochondrial Glycerol-3-Phosphate Acyltransferase (GPAM) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4569US2025017929A1Methods Of Treating Skin Cancer With Carboxypeptidase Vitellogenic Like (CPVL) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4669US2025134920A1Treatment Of Myeloid Cell Dysfunction With Membrane Spanning 4-Domains A6A (MS4A6A) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4768US12472241B2Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitorsREGENERON PHARMA·Filed 2019·Granted Nov 18, 2025·0 cites·7 claims
- 4868US2025115918A1Treatment Of Uveitis With Endoplasmic Reticulum Aminopeptidase 1 (ERAP1) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 4967US2025129371A1Treatment Of Macular Degeneration With Complement Factor D (CFD) InhibitorsREGENERON PHARMA·Filed 2024·Application pending·0 cites
- 5066US12186378B2Methods of treating skin cancer with histidine ammonia-lyase (HAL) agonistsREGENERON PHARMA·Filed 2022·Granted Jan 7, 2025·0 cites·10 claims
Showing the top 50 of 93 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Aris Baras files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →